183 related articles for article (PubMed ID: 37775115)
1. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775115
[TBL] [Abstract][Full Text] [Related]
2. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
bioRxiv; 2023 Feb; ():. PubMed ID: 36798179
[TBL] [Abstract][Full Text] [Related]
3. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
Depontieu FR; Qian J; Zarling AL; McMiller TL; Salay TM; Norris A; English AM; Shabanowitz J; Engelhard VH; Hunt DF; Topalian SL
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12073-8. PubMed ID: 19581576
[TBL] [Abstract][Full Text] [Related]
5. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
6. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
7. Tumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived From Cancer Signaling in Colorectal Cancer.
Penny SA; Abelin JG; Malaker SA; Myers PT; Saeed AZ; Steadman LG; Bai DL; Ward ST; Shabanowitz J; Hunt DF; Cobbold M
Front Immunol; 2021; 12():723566. PubMed ID: 34504498
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
J Immunother; 2007; 30(5):499-505. PubMed ID: 17589290
[TBL] [Abstract][Full Text] [Related]
9. Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry.
Abelin JG; Trantham PD; Penny SA; Patterson AM; Ward ST; Hildebrand WH; Cobbold M; Bai DL; Shabanowitz J; Hunt DF
Nat Protoc; 2015 Sep; 10(9):1308-18. PubMed ID: 26247297
[TBL] [Abstract][Full Text] [Related]
10. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
Elife; 2020 Apr; 9():. PubMed ID: 32314731
[TBL] [Abstract][Full Text] [Related]
11. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self.
Mohammed F; Cobbold M; Zarling AL; Salim M; Barrett-Wilt GA; Shabanowitz J; Hunt DF; Engelhard VH; Willcox BE
Nat Immunol; 2008 Nov; 9(11):1236-43. PubMed ID: 18836451
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
14. Analyzing the effect of peptide-HLA-binding ability on the immunogenicity of potential CD8+ and CD4+ T cell epitopes in a large dataset.
Wang S; Li J; Chen X; Wang L; Liu W; Wu Y
Immunol Res; 2016 Aug; 64(4):908-18. PubMed ID: 27094547
[TBL] [Abstract][Full Text] [Related]
15. A Molecular Basis for the Presentation of Phosphorylated Peptides by HLA-B Antigens.
Alpízar A; Marino F; Ramos-Fernández A; Lombardía M; Jeko A; Pazos F; Paradela A; Santiago C; Heck AJ; Marcilla M
Mol Cell Proteomics; 2017 Feb; 16(2):181-193. PubMed ID: 27920218
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients.
Lulu AM; Cummings KL; Jeffery ED; Myers PT; Underwood D; Lacy RM; Chianese-Bullock KA; Slingluff CL; Modesitt SC; Engelhard VH
Cancer Immunol Res; 2021 Nov; 9(11):1327-1341. PubMed ID: 34413086
[TBL] [Abstract][Full Text] [Related]
17. MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.
Zarling AL; Obeng RC; Desch AN; Pinczewski J; Cummings KL; Deacon DH; Conaway M; Slingluff CL; Engelhard VH
Cancer Res; 2014 Dec; 74(23):6784-95. PubMed ID: 25297629
[TBL] [Abstract][Full Text] [Related]
18. Is there MHC Class II restriction of the response to MHC Class I in transplant patients?
Papassavas AC; Barnardo MC; Bunce M; Welsh KI
Transplantation; 2002 Feb; 73(4):642-51. PubMed ID: 11889447
[TBL] [Abstract][Full Text] [Related]
19. Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells.
Falk CS; Steinle A; Schendel DJ
J Exp Med; 1995 Oct; 182(4):1005-18. PubMed ID: 7561674
[TBL] [Abstract][Full Text] [Related]
20. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy.
Zarling AL; Polefrone JM; Evans AM; Mikesh LM; Shabanowitz J; Lewis ST; Engelhard VH; Hunt DF
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14889-94. PubMed ID: 17001009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]